|
Making GREAT STRIDES--Exciting Research News! |
|
News from CF -
Latest News from CF
|
|
Saturday, 12 April 2008 21:49 |
Dear Friend,
We have exciting news! Last week, we announced promising results from an early Phase 2 study of VX-770, an oral compound developed in collaboration with Vertex Pharmaceuticals that targets a basic defect in cystic fibrosis.
This is the first time that any potential therapy has improved the abnormal sweat chloride (salt) levels in a person with CF.
We are very pleased with these results, but much more work remains to be done to ensure a brighter future for people with CF. Your support is crucial for us to make further progress.
|
|
Last Updated ( Saturday, 26 April 2008 17:18 )
|